For men with metastatic castration-resistant prostate cancer, PARP inhibitors represented a hard-won therapeutic advance — but only for a subset of patients, and clinical combinations with checkpoint blockade have repeatedly underwhelmed. New mechanistic evidence now explains a key reason why, and points toward a more precisely targeted combination strategy that could broaden benefit beyond patients with DNA-repair deficiencies.
Using bulk RNA sequencing on prostate cancer cells treated with olaparib, investigators identified a striking and previously underappreciated adaptive response: robust upregulation of CD73 (encoded by NT5E), an ectoenzyme that converts extracellular AMP into immunosuppressive adenosine. This induction was confirmed across both human and murine prostate cancer lines and was amplified in PTEN-knockout cells with homologous recombination repair compromise. Mechanistically, olaparib drives CD73 expression through two converging pathways — the DNA-damage-sensing ATR–CHEK1–IRF1 axis and TGF-β1–AKT signaling — essentially co-opting the drug's own damage response to shield tumors from immune attack. Olaparib simultaneously activated type I interferon signaling and antigen presentation, meaning the drug creates immunogenic conditions that the CD73-adenosine axis then actively suppresses. In preclinical in vivo models spanning both HRR-proficient and PTEN-null tumors, combining olaparib with CD73 blockade significantly delayed tumor growth, improved T-cell infiltration, and enhanced CD8⁺ effector function.
This work reframes why PD-1/PD-L1 combinations with PARP inhibition have struggled: tumors may be responding to immunogenic pressure by elevating an orthogonal adenosine checkpoint rather than PD-L1 alone. CD73 has attracted growing interest as an immunotherapy target, with several anti-CD73 antibodies already in early clinical trials for other solid tumors. The dual mechanistic convergence on CD73 — through both DNA-damage signaling and TGF-β — suggests the resistance is pharmacologically durable and unlikely to resolve spontaneously. Key limitations include reliance on preclinical mouse models and cell lines, with no human trial data yet. If translatable, this finding could redefine combination strategies for the large fraction of mCRPC patients currently excluded from PARP inhibitor benefit.